Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (62)

2021

  1. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor β inducing fibrotic responses

    Mucosal Immunology, Vol. 14, Núm. 2, pp. 377-388

2019

  1. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients

    PLoS ONE, Vol. 14, Núm. 1

  2. MUC1 intracellular bioactivation mediates lung fibrosis

    Thorax, Vol. 75, Núm. 2, pp. 132-142

  3. Mucin 1 deficiency mediates corticosteroid insensitivity in asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 1, pp. 111-121

2018

  1. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

    Thorax, Vol. 73, Núm. 6, pp. 519-529

  2. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

    Respiratory Research, Vol. 19, Núm. 1

  3. The JAK2 pathway is activated in idiopathic pulmonary fibrosis

    Respiratory Research, Vol. 19, Núm. 1

2016

  1. Evaluation of mucociliary clearance by three dimension micro-CT-SPECT in Guinea pig: Role of Bitter taste agonists

    PLoS ONE, Vol. 11, Núm. 10

  2. Molecular based drug targets for idiopathic pulmonary fibrosis

    Current Respiratory Medicine Reviews, Vol. 12, Núm. 3, pp. 186-207

  3. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

    Respiratory Research, Vol. 17, Núm. 1

  4. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: An ex vivo/in vitro study

    European Respiratory Journal, Vol. 47, Núm. 6, pp. 1737-1749

2015

  1. Pharmacological Assessment of the In Vitro Functional Selectivity of Aclidinium Bromide at M3 and M2 Muscarinic Receptors in Human Tissue

    Pulmonary Therapy, Vol. 1, Núm. 1, pp. 103-107

  2. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

    Respiratory Research, Vol. 16, Núm. 1

  3. Roflumilast prevents the metabolic Effects of bleomycin-induced fibrosis in a murine model

    PLoS ONE, Vol. 10, Núm. 7

2013

  1. Aclidinium inhibits cigarette smoke-induced lung fibroblast-to- myofibroblast transition

    European Respiratory Journal, Vol. 41, Núm. 6, pp. 1264-1274

  2. Bafetinib inhibits functional responses of human eosinophils in vitro

    European Journal of Pharmacology, Vol. 715, Núm. 1-3, pp. 172-180

2012

  1. Aclidinium inhibits human lung fibroblast to myofibroblast transition

    Thorax, Vol. 67, Núm. 3, pp. 229-237

  2. Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries

    European Respiratory Journal, Vol. 39, Núm. 4, pp. 927-938

  3. Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models

    Journal of Pharmacology and Experimental Therapeutics, Vol. 342, Núm. 2, pp. 497-509

  4. Piclamilast inhibits the pro-apoptotic and anti-proliferative responses of A549 cells exposed to H 2O 2 via mechanisms involving AP-1 activation

    Free Radical Research, Vol. 46, Núm. 5, pp. 690-699